Literature DB >> 34264527

Cycle threshold values in RT-PCR to determine dynamics of SARS-CoV-2 viral load: An approach to reduce the isolation period for COVID-19 patients.

Clara Aranha1, Vainav Patel2, Vikrant Bhor1, Dimpu Gogoi2.   

Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) has affected all inhabited continents, and India is currently experiencing a devastating second wave of coronavirus disease-2019 (COVID-19). Here, we examined the duration of clearance of SARS-CoV-2 in respiratory samples from 207 infected cases by real-time reverse-transcription polymerase chain reaction (RT-PCR). A substantial proportion of COVID-19 positive cases with cycle threshold (Ct) values more than or equal to 31 (45.7%) were subsequently tested negative for SARS-CoV-2 RNA within 7 days of initial detection of the viral load. A total of 60% of all the patients with COVID-19, irrespective of their Ct values, cleared SARS-CoV-2 RNA within 14 days of the initial detection. Longitudinal assessment of RT-PCR test results in individuals requiring 15-30 days to clear SARS-CoV-2 RNA showed a significant reduction of the viral load in samples with high or intermediate viral loads (Ct values ≤ 25 and between 26 and 30, respectively) but the follow-up group with low viral RNA (Ct values ≥ 31) exhibited a stable viral load. Together, these results suggest that COVID-19 positive cases with Ct values more than or equal to 31 require reduced duration to clear SARS-CoV-2, and thus, a shorter isolation period for this group might be considered to facilitate adequate space in the COVID Care Centres and reduce the burden on healthcare infrastructure.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID 19; RT-PCR; SARS-CoV-2; cycle threshold value; isolation

Mesh:

Substances:

Year:  2021        PMID: 34264527      PMCID: PMC8426941          DOI: 10.1002/jmv.27206

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


INTRODUCTION

Coronavirus disease‐2019 (COVID 19) caused by severe acute respiratory syndrome coronavirus (SARS‐CoV‐2) is a serious global health threat that the world is facing since December 2019. India reported the first confirmed case of COVID‐19 on January 30, 2020, and the cases rose exponentially in the next 8 months, the highest peak was recorded in the middle of September and then the caseload started declining for the next few months. However, India is witnessing the second wave of COVID‐19 pandemic since the first half of April 2021. The raging wave has greatly impacted the healthcare system with a deficiency in beds, oxygen, and medical supplies. The respiratory illness is transmitted in the community through respiratory droplets and contacts of infected people. , SARS‐CoV‐2 infection could be asymptomatic or symptomatic and the viral load is not associated with disease severity. The most common symptoms reported in patients are fever, fatigue, sore throat, dry cough, and breathlessness whereas headache, dizziness, abdominal pain, diarrhea, nausea, and vomiting are the less common symptoms. Real‐time reverse‐transcription polymerase chain reaction (RT‐PCR) test has been routinely used as the diagnostic test to detect SARS‐CoV‐2 nucleic acids in respiratory specimen swabs from throat, nasopharynx, and nose of individuals suspected of COVID‐19 during the acute phase of infection. Different viral target genes have been used for the detection of SARS‐CoV‐2, including spike (S), nucleocapsid (N), RNA‐dependent RNA polymerase (RdRp), open reading frame (ORF) 1 (O), and envelope (E). A fully automated assay, such as the Cobas platform uses a two‐target RT‐PCR for detecting SARS‐CoV‐2: O‐gene, a nonstructural region (ORF‐1) that is specific for SARS‐CoV‐2 (target 1) and E‐gene, a structural envelope region that is common to all Sarbecovirus subgenus (target 2). , Cycle threshold (Ct) values in RT‐PCR have been used to measure the amplification needed for the target viral gene to cross the threshold and are inversely related to the viral load. Detection of viral load is important to prevent the potential transmission of infection. A period of 14 days' isolation is generally recommended throughout the world to prevent the spread of SARS‐CoV‐2. Increased age was positively associated with prolonged RT‐PCR positivity. Although SARS‐CoV‐2 RNA shedding can be detected for an extended period, the duration of a live virus is relatively short‐lived. In this study, we compared the duration of SARS‐CoV‐2 viral RNA in individuals with different Ct values and evaluated the dynamics of viral load in cases that required 15–30 days to clear SARS‐CoV‐2 viral RNA.

MATERIALS AND METHODS

A total of 2233 nasopharyngeal swab specimens from outpatients and inpatients were collected in HiViral Transport Medium (Himedia) from COVID Care Centres in Mumbai. These samples were transferred to the laboratory under cold chain conditions within 12 h. The Cobas SARS‐CoV‐2 real‐time RT‐PCR assay was performed on the Cobas 6800 platform as per the manufacturer's instructions (Roche Molecular Diagnostics). Briefly, after loading the samples, nucleic acid extraction and subsequent real‐time RT‐PCR on the ORF1/a nonstructural region (O‐gene) that is specific for SARS‐CoV‐2 (target 1), a structural envelope gene (E‐gene) that is common to all Sarbecovirus subgenus (target 2) and an internal control RNA (noninfectious RNA in bacteriophage) are automatically performed by the platform. If detected, a Ct or cycle threshold value is obtained for each gene. Statistical analyses were performed using GraphPad Prism version 5.0, the Mann–Whitney test was used as the test of significance, and Spearman's rank correlation was used for correlation analysis.

RESULTS

A total of 1500 (67%) samples collected from the COVID Care Centres were tested positive for SARS‐CoV‐2. Of these positive cases, 207 individuals were followed until the viral load was reduced to an undetectable level by RT‐PCR. Based on the Ct values, it was observed that a decreased Ct value or higher viral load was linked to extended SARS‐CoV‐2 RNA shedding. As shown in Figure 1, a proportion of 79.2% cases with Ct values less than or equal to 25 compared with 39.5% cases with Ct values between 26%–30% and 33.6% cases with Ct values more than or equal to 31 required 15–30 days to clear SARS‐CoV‐2 viral load. We also found that 17.1% and 28.6% of individuals having low viral load (Ct values ≥ 31) were able to clear SARS‐CoV‐2 RNA within 3 days and 7 days, respectively (Figure 1). The Ct values of SARS‐CoV‐2 were positively correlated with the duration of the viral clearance (p < 0.0001 and r = 0.77). Other factors, such as the symptomatic COVID‐19, underlying medical condition (UMC), and age were not correlated with the duration of virus clearance (data not shown).
Figure 1

Distribution of COVID‐19 cases that tested negative when followed up over a period of 30 days at 3 days, 7 days, between 8 and 14 days, and between 15 and 30 days. Stacked graph bar chart depicts the COVID‐19 cases that tested negative for SARS‐CoV‐2 RNA in individuals with Ct values of ≤25, 26–30, and ≥31, respectively at the mentioned follow‐up days. COVID‐19, coronavirus disease 2019; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2

Distribution of COVID‐19 cases that tested negative when followed up over a period of 30 days at 3 days, 7 days, between 8 and 14 days, and between 15 and 30 days. Stacked graph bar chart depicts the COVID‐19 cases that tested negative for SARS‐CoV‐2 RNA in individuals with Ct values of ≤25, 26–30, and ≥31, respectively at the mentioned follow‐up days. COVID‐19, coronavirus disease 2019; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2 Furthermore, samples from 61 cases that required 15–30 days to clear SARS‐CoV‐2 were analyzed. The median age of this group was 50 years (22–77 years) with almost an equal ratio of symptomatic and asymptomatic cases, and 44 out of 61 (72%) individuals did not have any underlying medical conditions (Table 1). Notably, previous RT‐PCR tests between 8 and 14 days for individuals having high and intermediate viral load with initial Ct values of less than or equal to 25 and Ct values between 26 and 30, respectively showed a significant reduction in the SARS‐CoV‐2 (Figure 2A,B). However, cases having low viral load with Ct values more than 31 showed a consistent level of SARS‐CoV‐2 RNA between 8 and 14 days before becoming undetectable to RT‐PCR (Figure 2C).
Table 1

Description of the study group with prolonged SARS‐CoV‐2 viral shedding

Ct valuesClinical findingsUnderlying medical condition (UMC)Age (in years)Total follow‐up cases
SymptomaticAsymptomaticWith UMCWithout UMC>6045–6030–4518–30
Ct ≤ 258113162944 19
Ct 26–3067490733 13
Ct ≥ 311415101913970 29
Figure 2

Cycle threshold (Ct) values for the O and E genes at two‐time intervals of Day 0 (initial day of testing) and Day 8–14 in follow‐up patients that required 15–30 days to clear SARS‐CoV‐2 viral load. O‐gene stands for ORF1, a nonstructural region that is specific for SARS‐CoV‐2 (target 1) and E‐gene stands for a structural envelope gene that is common to all Sarbecovirus subgenus (target 2). Scatter plot showing Ct values for O and E genes with (A) Ct values of ≤25 (n = 19), (B) Ct values between 26 and 30 (n = 13), and (C) Ct values of ≥31 (n = 29). RT‐PCR tests between 8 and 14 days revealed a significantly lowered SARS‐CoV‐2 viral load in individuals with initial Ct values of ≤25 and Ct values between 26 and 30 (p < 0.0001), but there was no significant change in the viral load of individuals with initial Ct values of ≥31 (nonsignificant). Each dot represents an individual and the horizontal lines indicate mean values. The Mann–Whitney test was used as the test of significance. RT‐PCR, reverse‐transcription polymerase chain reaction; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2

Description of the study group with prolonged SARS‐CoV‐2 viral shedding Cycle threshold (Ct) values for the O and E genes at two‐time intervals of Day 0 (initial day of testing) and Day 8–14 in follow‐up patients that required 15–30 days to clear SARS‐CoV‐2 viral load. O‐gene stands for ORF1, a nonstructural region that is specific for SARS‐CoV‐2 (target 1) and E‐gene stands for a structural envelope gene that is common to all Sarbecovirus subgenus (target 2). Scatter plot showing Ct values for O and E genes with (A) Ct values of ≤25 (n = 19), (B) Ct values between 26 and 30 (n = 13), and (C) Ct values of ≥31 (n = 29). RT‐PCR tests between 8 and 14 days revealed a significantly lowered SARS‐CoV‐2 viral load in individuals with initial Ct values of ≤25 and Ct values between 26 and 30 (p < 0.0001), but there was no significant change in the viral load of individuals with initial Ct values of ≥31 (nonsignificant). Each dot represents an individual and the horizontal lines indicate mean values. The Mann–Whitney test was used as the test of significance. RT‐PCR, reverse‐transcription polymerase chain reaction; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2

DISCUSSION

Detection of viral nucleic acid by RT‐PCR is considered as a gold standard viral diagnostic assay. The use of automated RT‐PCR assays for mass screening of individuals for SARS‐CoV‐2 has the advantage of minimal hands‐on time and accuracy of results over the conventional RT‐PCR. An automated assay, such as the Cobas 6800 test has the additional benefit of having a lower limit of detection. In this study, we have used automated SARS‐CoV‐2 assay on the Cobas 6800 platform to examine the dynamics of SARS‐CoV‐2 viral load and duration of RNA shedding We observed that individuals with an increased Ct value or lower viral load could clear SARS‐CoV‐2 viral RNA in a short duration, for instance, 66.4% of cases with Ct value more than or equal to 31 could clear the viral load within 14 days of initial detection. In contrast, only a small fraction of individuals (20.8%) with a Ct value less than or equal to 25 were able to clear the viral load during the same period. A total of 40% of all the patients with COVID‐19, irrespective of their Ct values, were positive for SARS‐CoV‐2 RNA even after 14 days of the initial detection. Nonetheless, detection of viral RNA by RT‐PCR fails to determine the presence of a replicative virus or viral infectivity. Several studies have shown that higher SARS‐CoV‐2 Ct values correspond to nonreplicative or noninfectious viral RNA, as determined by viral culture. , , , Longitudinal assessment of RT‐PCR test results in individuals requiring 15–30 days to clear SARS‐CoV‐2 RNA showed that groups with initial high viral load (Ct values ≤25) and intermediate viral load (Ct values 26–30) exhibited a significant reduction of viral load between 8 and 14 days. However, the case of the individuals having initial lower viral load with Ct values more than or equal to 31 showed consistent viral load at 8–14 days followed by the absence of SARS‐CoV‐2 RNA between days 15–‐30. Overall, a sizeable proportion of COVID‐19 positive individuals with Ct values more than or equal to 31 (45.7%) were able to clear SARS‐CoV‐2 RNA within 7 days and subsequent re‐testing of the individuals (33.6%) requiring a long time to clear the viral RNA (15–30 days) showed no significant changes in the viral load before becoming undetectable until Days 15–30. Additionally, we found that cases with Ct values more than or equal to31 and requiring 15–30 days to clear SARS‐CoV‐2 have a considerable proportion (76%) of individuals above 45 years of age and around 66% of them were without any underlying medical conditions, suggesting prolonged RNA shedding in these individuals. A small fraction of individuals with initial Ct values of more than or equal to 31 that showed prolonged SARS‐CoV‐2 RNA shedding (15–30 days), albeit without any significant change in their viral load between 8 and 14 days, maybe considered for subsequent home quarantine after 7 days, if there is no severity in the disease symptoms. Positive/negative SARS‐CoV‐2 diagnosis with Ct values could serve as a test‐based strategy and potential guide for patient management. In conclusion, our findings suggest categorization of SARS‐CoV‐2 positive cases based on their Ct values and subsequent considerations for home quarantine for individuals with less viral load. This approach would support dealing with the COVID‐19 pandemic and its successive waves that have overburdened the healthcare system and COVID Care Centres.

CONFLICT OF INTERESTS

The authors declare that there are no conflicts of interest.

AUTHOR CONTRIBUTIONS

Dimpu Gogoi conceived the study. Clara Aranha and Dimpu Gogoi collated the data and performed the data analysis. Testing and reporting of all the patient samples were carried out under the supervision of Vainav Patel and Vikrant Bhor. Dimpu Gogoi and Clara Aranha drafted the manuscript. All authors reviewed the manuscript and approved it for submission.
  14 in total

1.  Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples.

Authors:  Jared Bullard; Kerry Dust; Duane Funk; James E Strong; David Alexander; Lauren Garnett; Carl Boodman; Alexander Bello; Adam Hedley; Zachary Schiffman; Kaylie Doan; Nathalie Bastien; Yan Li; Paul G Van Caeseele; Guillaume Poliquin
Journal:  Clin Infect Dis       Date:  2020-12-17       Impact factor: 9.079

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  Virological assessment of hospitalized patients with COVID-2019.

Authors:  Roman Wölfel; Victor M Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Müller; Daniela Niemeyer; Terry C Jones; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Journal:  Nature       Date:  2020-04-01       Impact factor: 49.962

4.  Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic.

Authors:  Mario Poljak; Miša Korva; Nataša Knap Gašper; Kristina Fujs Komloš; Martin Sagadin; Tina Uršič; Tatjana Avšič Županc; Miroslav Petrovec
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

5.  To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value.

Authors:  Michael R Tom; Michael J Mina
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

6.  Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020.

Authors:  Jiaye Liu; Xuejiao Liao; Shen Qian; Jing Yuan; Fuxiang Wang; Yingxia Liu; Zhaoqin Wang; Fu-Sheng Wang; Lei Liu; Zheng Zhang
Journal:  Emerg Infect Dis       Date:  2020-06-17       Impact factor: 6.883

7.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

8.  SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis.

Authors:  Muge Cevik; Matthew Tate; Ollie Lloyd; Alberto Enrico Maraolo; Jenna Schafers; Antonia Ho
Journal:  Lancet Microbe       Date:  2020-11-19

9.  Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test.

Authors:  Elisabet Pujadas; Nnaemeka Ibeh; Matthew M Hernandez; Aneta Waluszko; Tatyana Sidorenko; Vanessa Flores; Biana Shiffrin; Numthip Chiu; Alicia Young-Francois; Michael D Nowak; Alberto E Paniz-Mondolfi; Emilia M Sordillo; Carlos Cordon-Cardo; Jane Houldsworth; Melissa R Gitman
Journal:  J Med Virol       Date:  2020-05-22       Impact factor: 20.693

10.  Cycle threshold values in RT-PCR to determine dynamics of SARS-CoV-2 viral load: An approach to reduce the isolation period for COVID-19 patients.

Authors:  Clara Aranha; Vainav Patel; Vikrant Bhor; Dimpu Gogoi
Journal:  J Med Virol       Date:  2021-07-23       Impact factor: 20.693

View more
  17 in total

1.  A paper-based optical sensor for the screening of viruses through the cysteine residues of their surface proteins: A proof of concept on the detection of coronavirus infection.

Authors:  Mahnaz D Gholami; Kristyan Guppy-Coles; Serena Nihal; Daman Langguth; Prashant Sonar; Godwin A Ayoko; Chamindie Punyadeera; Emad L Izake
Journal:  Talanta       Date:  2022-05-31       Impact factor: 6.556

2.  Clinical Application of Ultraviolet C Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 in Contaminated Hospital Environments.

Authors:  Wen-Lin Su; Chih-Pei Lin; Hui-Ching Huang; Yao-Kuang Wu; Mei-Chen Yang; Sheg-Kang Chiu; Ming-Yieh Peng; Ming-Chin Chan; You-Chen Chao
Journal:  Viruses       Date:  2021-11-26       Impact factor: 5.048

3.  Predictors of Illness Severity in COVID-19 Cases in Saudi Arabia.

Authors:  Reem Al Dossary; Amani Alnimr; Reem Aljindan; Khaled R Alkharsah; Ahmed K Al-Qurayn; Obeid Eltreifi; Feras A Alkuwaiti; Abdullah B Almashouf; Ahmed M Alsahlawi; Amal Alshammari; Dhoha Hudhaiah; Mohammed S Alshahrani; Huda Bukhari
Journal:  Infect Drug Resist       Date:  2021-10-05       Impact factor: 4.003

4.  Evaluation of reverse transcription-loop-mediated isothermal amplification for rapid detection of SARS-CoV-2.

Authors:  Willi Quino; Diana Flores-León; Junior Caro-Castro; Carmen V Hurtado; Iris Silva; Ronnie G Gavilan
Journal:  Sci Rep       Date:  2021-12-20       Impact factor: 4.379

5.  DirectDetect SARS-CoV-2 Direct Real-Time RT-PCR Study Using Patient Samples.

Authors:  Dulguunnaran Naranbat; Lindsay Schneider; Rami Kantor; Curt G Beckwith; Lauri Bazerman; Fizza Gillani; Sujata Sahu; Kim Rapoza; Soya Sam; Vlad Novitsky; Jimin Shin; Evelyn Hipolito; Isabella Diaz; Daniella Carnevale; Anubhav Tripathi
Journal:  ACS Omega       Date:  2022-02-07

6.  The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids.

Authors:  Vijairam Selvaraj; Arkadiy Finn; Jennifer Li; Kwame Dapaah-Afriyie
Journal:  Cureus       Date:  2022-02-25

7.  Postviral Gastroparesis Associated With SARS-CoV-2 Infection in a Pediatric Patient.

Authors:  Courtney M Rusch; Jerome M Molleston; Matthew F Glasser; Steven Don; Sakil S Kulkarni
Journal:  JPGN Rep       Date:  2022-03-09

Review 8.  Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms.

Authors:  Mahender Aileni; Gulab Khan Rohela; Phanikanth Jogam; Shakuntala Soujanya; Baohong Zhang
Journal:  Cells       Date:  2022-03-31       Impact factor: 6.600

9.  Cycle threshold values in RT-PCR to determine dynamics of SARS-CoV-2 viral load: An approach to reduce the isolation period for COVID-19 patients.

Authors:  Clara Aranha; Vainav Patel; Vikrant Bhor; Dimpu Gogoi
Journal:  J Med Virol       Date:  2021-07-23       Impact factor: 20.693

10.  Detection of the ORF1 Gene Is an Indicator of the Possible Isolation of Severe Acute Respiratory Syndrome Coronavirus 2.

Authors:  Kazuya Shirato; Masatoshi Kakizaki; Yuriko Tomita; Miyuki Kawase; Makoto Takeda
Journal:  Pathogens       Date:  2022-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.